Tanabe Pharma America transferring RADICAVA® business to Shionogi in U.S. and Canada, focusing on growth. Dec. 22, 2025.
A recent transaction between the U.S. and Canada has secured continued access to RADICAVA® for individuals with ALS. The deal, which took place on December 22, 2025, in Jersey City, New Jersey, involved Tanabe Pharma America, Inc. (TPA), a subsidiary focused on future growth and innovation. This move ensures ongoing availability of the medication for patients in need in both countries.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments